Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 116

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 116
---
2 preliminary dose expansion of the trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 research collaboration with Sanofi, the progression to the dose expansion part of the trial has triggered a milestone payment from Sanofi to Innate of €4 million. This amount was received by the Company on May 17, 2024.

Phase 1/2 clinical trial in combination

• In July 2024, Sanofi initiated a new Phase 1 / Phase 2, randomized, open label, multi-cohort, multi-center study (NCT06508489) assessing the safety, tolerability and preliminary efficacy of SAR’579 / IPH6101 administered in combination with azacitidine and venetoclax in patients with CD123 expressing hematological malignancies in newly diagnosed AML.

On April 23, 2025, the Company announced that, as part of the restructuring of the January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) and in alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Agreement as it relates to SAR’579/IPH6101 (CD123 ANKET), effective as of June 30, 2025. Innate will regain the rights on July 1, 2025. The Parties will discuss a transition plan with regard to ongoing studies

IPH6401/SAR’514, a BCMA-targeting NK Cell Engager

a. Mechanism

BCMA (B-Cell Maturation Antigen) is a protein expressed on the surface of mature B cells and plasma cells. It is essential for B cell survival and function. In multiple myeloma and other B-cell malignancies, BCMA is overexpressed on malignant plasma cells.

IPH6401/SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET®(Antibody-based NK cell Engager Therapeutics) proprietary platform.

b. Clinical trial

A Sanofi-sponsored Phase 1/2 clinical trial (NCT05839626) is evaluating SAR’514 /